June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Carboxymethylated Hyaluronic acid (CMHA-S)-based Ocular Delivery of Antibiotics
Author Affiliations & Notes
  • Hee-Kyoung Lee
    EyeGate Pharma, Salt Lake City, Utah, United States
    University of Utah, Salt Lake City, Utah, United States
  • Shirley Luo
    EyeGate Pharma, Salt Lake City, Utah, United States
    University of Utah, Salt Lake City, Utah, United States
  • Barbara M Wirostko
    EyeGate Pharma, Salt Lake City, Utah, United States
  • Brenda Mann
    EyeGate Pharma, Salt Lake City, Utah, United States
  • Footnotes
    Commercial Relationships   Hee-Kyoung Lee, EyeGate Pharma (F), EyeGate Pharma (E), EyeGate Pharma (R); Shirley Luo, EyeGate Pharma (F), EyeGate Pharma (R); Barbara Wirostko, EyeGate Pharma (F), EyeGate Pharma (E), EyeGate Pharma (R), EyeGate Pharma (P); Brenda Mann, EyeGate Pharma (F), EyeGate Pharma (E)
  • Footnotes
    Support  NSF SBIR Phase 2 (Award # 1430921).
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4119. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hee-Kyoung Lee, Shirley Luo, Barbara M Wirostko, Brenda Mann; Carboxymethylated Hyaluronic acid (CMHA-S)-based Ocular Delivery of Antibiotics. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4119.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal ulcers, an ocular emergency and a leading cause of blindness globally, require compounded off label topical antibiotics, often at an inconvenient hourly round-the-clock multiple day administration. A topical CMHA-S biodegradable film that delivers small molecules in sustained-released formulation to overcome this challenge has been developed. Using Besifloxacin as a target drug, in vitro feasibility of the novel film product was assessed

Methods : Films were fabricated in silicone-based molds using CMHA-S and poly(ethyleneglycol) diacrylate (PEGDA) as a cross-linker. Various amounts of Besifloxacin-HCl (150, 300, 750, and 1500 μg) were formulated into the polymer solution prior to cross-linking. Polymerized CMHA-S gels were dried at room temperature overnight to create thin films. Drug release in phosphate buffered saline (PBS) was monitored by UV absorption. Released drug was calculated from the Besifloxacin standard solution. Besifloxacin-loaded films were sterilized using ethylene oxide (EtO). The efficacy against both S. aureus and P. aeruginosa was tested by Zone of Inhibition (ZOI).

Results : Besifloxacin was released until 56 days (11, 16, 56, and 56 days for 150, 300, 750, and 1500 μg-loaded films, respectively). The monitoring was stopped when the daily released amount reached 1 μg. For all 4 films, the released amount at day 7 was greater than 10 μg, which was efficacious in ZOI studies against both S. aureus and P. aeruginosa. Efficacy was similar for both pre- and post-sterilized films.

Conclusions : Besifloxacin-containing CMHA-S films yielded reproducible in vitro release for up to 56 days. This film can ultimately be a commercially viable product to meet the medical needs of a single-application ocular antibiotic to avoid hourly dosing. Furthermore, this system can be expanded to deliver other molecules to treat additional ocular pathologies.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×